Warning Letter — Telos Trading Limited dba Alwinshop
The FDA Center for Drug Evaluation and Research issued a Warning Letter to Telos Trading Limited, doing business as Alwinshop, on June 17, 2026.
This action affects Telos Trading Limited (dba Alwinshop) and personnel responsible for online marketing, labeling, and regulatory compliance for products sold via their digital platforms.
The issuance of a Warning Letter from CDER typically indicates that the FDA has identified significant violations of the Federal Food, Drug, and Cosmetic Act, often involving the marketing of unapproved new drugs or misbranded products. This suggests that the company's online marketing claims may have crossed into therapeutic territory without required safety and efficacy data or formal approvals.
Regulatory teams should conduct immediate audits of online storefronts and marketing materials to ensure no unauthorized drug claims are present. QA should verify that products marketed as supplements or other non-drug items do not meet the legal definition of a drug through stated therapeutic intent.
FDA Warning Letter issued to: Telos Trading Limited dba Alwinshop. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/telos-trading-limited-dba-alwinshop-729062-06172026
Open in openFDA / FDA.gov